Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO

Jeff Jonas Remains As Chief Innovation Officer, Board Member

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.

Barry Greene
Barry Greene's first day as Sage CEO was 15 December • Source: Sage Therapeutics Inc.

Barry Greene was interested in pursuing opportunities related to central nervous system diseases when the long-time Alnylam Pharmaceuticals Inc. president made the decision to move on. Already familiar with Sage Therapeutics, Inc. and unable to take a long vacation between executive gigs due to the COVID-19 pandemic, Greene told Scrip, the opportunity to lead CNS drug developer Sage as its new CEO was a “no-brainer” – pun intended.

Greene’s new role was revealed on 16 December, but Sage’s prior CEO Jeff Jonas isn’t going anywhere. Jonas will remain...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Nabil

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.